<DOC>
	<DOC>NCT02767414</DOC>
	<brief_summary>The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza A as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). The secondary aims are to: Validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza B as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); Evaluate the correct interpretation of the Respirio Flu Test by subjects with influenza-like symptoms; Evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test.</brief_summary>
	<brief_title>Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Male and female subjects aged ≥ 1 year; Rhinorrhea; ≤ 5 days from onset of influenzalike illness symptoms; Subject (or parent/legal guardian) capable and willing to give informed consent/assent; Subject (or parent/legal guardian) able to read and write English. Has undergone treatment with antivirals within the previous 7 days; Has been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days; Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months; Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent; Has had prior exposure to the Respirio Flu Test or eLab Flu Test.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>